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ABSTRACT
Although the increased risk of developing sporadic Alzheimer’s disease (AD)
associated with the inheritance of the apolipoprotein E4 (APOE4) allele is well
characterized, the molecular underpinnings of how ApoE4 imparts risk remains
unknown. Enhanced proteolysis of the ApoE4 protein with a toxic-gain of function has
been suggested and a 17 kDa amino-terminal ApoE4 fragment (nApoE41-151) has been
identified in post-mortem human AD frontal cortex sections. Recently, we demonstrated
in vitro, exogenous treatment of nApoE41-151 in BV2 microglial cells leads to uptake,
trafficking to the nucleus and increased expression of genes associated with cell toxicity
and inflammation. In the present study, we extend these findings to zebrafish (Danio
rerio), which is an emerging in vivo model system to study AD. Exogenous treatment of
nApoE41-151 to 24-hour post-fertilization for 24 hours resulted in significant mortality. In
addition, developmental abnormalities were observed following exogenous treatment
with nApoE41-151 including improper folding of the hindbrain, delay in ear development,
deformed yolk sac, enlarged cardiac cavity, and significantly lower heart rates. Decreased
presence of pigmentation was noted for nApoE41-151 treated fish compared with controls.
Touch-evoked responses to stimuli were negatively impacted by treatment with nApoE41151.

A similar nApoE31-151 fragment that differs by a single amino acid change (C>R) at

position 112 had no effects on these parameters under identical treatment conditions.
Additionally, triple-labeling confocal microscopy not only confirmed the nuclear
localization of the nApoE41-151 fragment within neuronal populations following
vi

exogenous treatment, but also identified the presence of tau tangle pathology, one of the
hallmark features of AD. Collectively, these in vivo data demonstrating toxicity as well as
sublethal effects on organ and tissue development support a novel pathophysiological
function of this AD associated-risk factor.
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CHAPTER ONE: INTRODUCTION
Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disease encompassing the most
prevalent form of dementia characterized by beta-amyloid plaques (βAP) and
neurofibrillary tangles (NFTs) (DeTure & Dickson, 2019; Martins et al., 2006). Earlyonset AD has been associated with autosomal-dominant mutations in the amyloid
precursor gene (APP), presenlin-1 and -2 (PSEN1/PSEN2) genes (Martins et al., 2006).
These mutations collectively comprising what is known as early-onset AD, affect
approximately 5% of all known AD cases (Association, 2019). The majority of AD cases
are characterized as late-onset in which the highest risk factors for the disease are
environmental (e.g., aging and lifestyle choices) in addition to the inheritance of an
apolipoprotein (APOE) allele, namely apolipoprotein E4 (APOE4) (Martins et al., 2006).
The APOE gene has several isoforms of importance that are affected by a cysteine to
arginine polymorphism: APOE2 (C112, C158), APOE3 (C112, R158), and APOE4 (R112, R158)
(Munoz et al., 2018; Weisgraber, 1994). A carrier of the APOE4 allele increases the risk
of developing AD by four to twelve-fold (Martins et al., 2006). However, the
mechanisms of how ApoE4 contributes to increased risk of disease have remained
elusive.
ApoE4 Structure and Function
The APOE gene encodes the main cholesterol transporter protein (ApoE) in the
CNS that is associated with use of low-density lipoprotein receptor (LDLR) family
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(Goldstein & Brown, 1976; Innerarity & Mahley, 1978). Cholesterol transport in both the
periphery and the CNS are vital for basal cellular function, but neurons are in critical
need of adequate supply for synaptogenesis and neurite outgrowth (Xie et al., 2003). Full
length ApoE isoforms are 299 amino acids (AA) long with a molecular weight (MW) of
34 kDa. ApoE has 2 major domains: a lipoprotein receptor binding N-terminal, a lipid
and Aβ binding C-terminal that connect via a hinge region (Mahley, 2016). The ApoE
isoforms differ in receptor binding affinity through the stepwise change in cysteine (C) to
arginine (R) from ApoE2 to ApoE4 (Weisgraber, 1994). The C112 to R112 mutation alters
the side chain orientation of ApoE4 compared to ApoE2 and ApoE3 through the
formation of a salt bridge combining R112 to E109 (Buttini et al., 1999; Weisgraber, 1994;
Xie et al., 2003). Changes in the conformational structure of the isoforms from the C to R
substitutions leads to an increased likelihood of the proteolysis for ApoE4>
ApoE3>ApoE2 by exposing previously confined proteolytic cleavage sites in the hinge
region (Harris et al., 2003). The role of ApoE4 proteolysis as an early pathophysiological
event for AD development has been supported through the findings of fragments that
hold neurotoxic effects on the CNS with varying degrees of severity that appear
dependent on size and location of the fragmentation of ApoE (Dafnis et al., 2012; Zhou et
al., 2006). Size and location of the fragmentation events is dependent on the cleavage
enzymes utilized. Our lab formerly presented data on an ApoE4 fragment identified in the
prefrontal cortex from post-mortem AD patient tissue and that localize within NFTs
(Rohn et al., 2012). Our findings demonstrated that exogenous application of a smaller
amino-terminal fragment of ApoE4 (nApoE41-151) that is 1-151 amino acids in length to
microglial cells resulted in uptake of nApoE41-151, trafficking to microglial nuclei, and the
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upregulated expression of genes associated with inflammation (Cho et al., 2001; Love et
al., 2017) Our previous findings also supported a role for the matrix metalloproteinase-9
(MMP-9) in generating this fragment due to its’ ability to cleave ApoE4 at D154
generating a 17 kDa fragment as observed previously within AD post-mortem brain
tissue (Love et al., 2017). MMP-9 and ApoE have both previously been linked to the
activation of inflammatory pathways within the context of AD (Cho et al., 2001).
However, increased prevalence of proteolysis for ApoE4 is only a piece to this puzzle.
The fragmentation of ApoE4 into a 17 kDa fragment via MMP-9 occurs in the
extracellular matrix. Studies investigating the downstream effects of fragmentation have
demonstrated localization of fragments in cell nuclei, where ApoE4 fragments have the
potential to act as transcription factors to upregulate inflammatory responses in microglia
and neurons (Dafnis et al., 2012; Gottschall & Deb, 1996). The missing link between
these steps is the process of re-internalizing the ApoE fragment once it has been cleaved.
Interaction with low-density lipoprotein receptor related protein (LRP) and a thrombincleaved 22 kDa N-terminus ApoE4 fragment showcase a plausible uptake mechanism via
receptor mediated endocytosis (Tolar et al., 1997). This uptake by the LRP is typically
observed with lipoprotein bound ApoE but is seen to occur with un-enriched ApoE in the
case of fragmentation where the LDL binding region is intact (Narita et al., 2002; Wilson
et al., 1991). Once the smaller fragment can re-enter the intracellular environment,
ApoE4 fragments are able to diffuse through the nuclear pore to act as potential
regulators of gene expression. The process detailed above describes a model in which
ApoE4 has the propensity to play a direct role in the pathophysiological progression of
AD through actions as a transcription factor in upregulating pro-inflammatory responses.
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The results previously described by our lab were generated using a transformed BV2
microglial cell line, in vitro, to understand the potential effects of the fragment in the
cellular environment; this data has been expanded within my thesis to provide biological
context to the results through an in vivo study on the organismal effects of ApoE4
fragmentation by utilizing a vertebrate animal model: zebrafish (Danio rerio).
Zebrafish as a Model for Alzheimer’s Disease
The zebrafish model system has increasingly been used to study neurobiological
questions in vertebrates. Some of the many benefits to this model are the rapid growth
cycle, high fecundity rates, transparency of embryogenesis via externally fertilized
embryos, and the early generation of stereotyped behavior during embryonic and larval
stages (Gottschall & Deb, 1996; Narita et al., 2002; Tolar et al., 1997). Documentation of
the zebrafish embryogenesis process has been well-documented for organ, tissue, cell,
and molecular contexts. The zebrafish has a duplicated genome with split or lost function
among the duplicated genes (Horzmann & Freeman, 2018). The zebrafish, while not as
complex as a rodent model, shares many developmental conserved neurochemical and
neuroanatomical pathways with humans (Beckers et al., 2019; Nesan & Vijayan, 2012).
While not all structures in human brains are directly transferrable in structure to the
zebrafish brain, comparable cellular networks exist which follow similar developmental
progression to humans (Kimmel et al., 1995; Schmidt et al., 2013). An applicable
example for our research is the lack of a formalized hippocampus region in zebrafish.
The hippocampus is recognized as the primary location for memory integration and
retention in the human brain which takes on heavy burden with Aβ and NFT
accumulation in AD (He et al., 2018). Zebrafish lack a defined structure to date for a
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zebrafish hippocampus, a comparative neuronal population in the pallium has been
shown to function as an effective homologue to the hippocampus in mammals which then
provides a function comparison (Portavella et al., 2004; Vargas et al., 2012). In addition
to structural similarity, zebrafish contain orthologs for genes associated with the
progression of AD in humans such as those demonstrated in Table 1. Ortholog presence
can provide realistic expectations for the biological mechanisms that take place for ADassociated abnormalities such as the presence of mapta and maptb in zebrafish. The mapt
orthologues in zebrafish correspond to the human MAPT which encodes for a protein
highly correlated with neurodegenerative disease: Tau. Tau is a microtubule associated
protein (MAP) which is hyperphosphorylated in AD leading to aggregation into what are
known as tau tangles (DeTure & Dickson, 2019). The endogenous presence of tau via
mapta and maptb create ample model to study the development of tauopathies. The
combined attributes of the zebrafish model system make it an ideal vertebrate species to
add biological relevance to AD research.
Hypothesis
My thesis using zebrafish represented a logical progression of previous work in
the lab following the in vitro BV2 cell culture studies (Love et al., 2017; Pollock et al.,
2020; Pollock et al., 2019). Other studies have demonstrated the neurotoxic effects of
fragmentation in ApoE4 as well as neuroprotective effects of ApoE3 fragmentation
(Buttini et al., 1999; Tolar et al., 1997). Based on prior data completed in vitro, data
supporting the role in a vertebrate system is necessary to understand the role of ApoE
fragmentation in a complex tissue environment. The overarching hypothesis of my thesis
is that treatment of zebrafish embryos with nApoE41-151 will lead to morphological,
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behavioral, and molecular abnormalities supporting the role of ApoE4 fragmentation as a
crucial step in AD pathogenesis.

Overview of AD associated genes in human versus zebrafish.

MAPT

APP

APOE

Name

Zebrafish
Gene(s)
apoea
apoeb
appa
appb
mapta
maptb
CNS, maptb only in spinal
cord

CNS

Axonal outgrowth,
synaptogenesis
microtubule binding

Retina, YSL, CNS

Location(s)

Cholesterol Transport

Function(s)

Sequence
Homology
27.5%
25.6%
70.0%
67.0%
43.8%
57.0%

Gene sequence analyses can be compared to understand similarities between human and protein similarity.

Table 1.

Tables

(Babin et al.,
2014)
(Musa et al.,
2001)
(Howe et al.,
2020)

References
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CHAPTER TWO: MORPHOLOGICAL EFFECTS
Overview
As an initial approach, we examined the developmental effects of exogenous
treatment of hatching stage zebrafish embryos following treatment with nApoE41-151 at
the beginning of the segmentation period. The timepoint of 24 hours were chosen as a
starting point for treatment because after 24 hours post-fertilization (hpf), embryo
survivability in untreated control AB-wild-type (ABWT) embryos were 100%. From 0
hpf to 24 hpf, embryos had approximately 75-80% survival which can confound data on
survivability within that time frame. Due to the steep curve in survivability prior to 24
hpf, treatment was initiated between the somite-19 and prim-5 stages (Kimmel et al.,
1995). A set staging range during the treatment of zebrafish was applied by gauging the
stages of development through Kimmel et al. (1995) standards (Table 2). For zebrafish,
embryogenesis is asynchronous both across and within clutches which can lead to
misrepresentation of development progress across embryos without an applied set
standardization (Kimmel et al., 1995). Primarily, for treatment, head to tail positioning,
and the counting of somite under a microscope were employed to determine the staging
period of each embryo selected as shown. The selection process during treatment was
vital in allowing analysis of developmental features in a constructive format that allowed
results on development to be compared across groups in this project. This chapter
employed a semi-qualitative scale, heart rate measurements, and survivability to inform
observations about zebrafish development across treatment groups for non-treated
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zebrafish (control), nApoE31-151, and nApoE41-151 treated samples. My working
hypothesis is that nApoE41-151 will show developmental progress that is disrupted when
compared to untreated controls or to nApoE31-151 treated samples.
Materials and Methods
Synthesis of nApoE1-151 fragments
Generation of nApoE41-151 and nApoE31-151 including synthesis of plasmids,
expression in E. coli, and purification (>85% purity) was contracted out to GenScript Inc.
(Piscataway, NJ). A 6X His-tag at the C-terminal end was added to facilitate purification.
The protein fragments are identical aside from the C112 to R112 replacement in nApoE41151.

The verification of proteins was rigorous with each preparation including a certificate

of analysis that includes DNA sequencing, SDS PAGE, and western blot by using
standard protocols for molecular weight and purity measurements. The concentration of
recombinant proteins was determined by Bradford protein assay with BSA as a standard.
Characterization of nApoE41-151 in our laboratory was assessed by ELISA and western
blot analysis utilizing an anti-His antibody as previously described in (Pollock et al.,
2019). A similar fragment to apoE3 (nApoE31-151) was utilized to directly compare the
differences in toxicity and nuclear localization between nApoE41-151 and nApoE31-151.
Zebrafish Embryo Care and Maintenance
Animal husbandry and colony maintenance was handled by the Boise State
University vivarium system. All animal protocols are coordinated with the Boise State
University IACUC committee in accordance with recommendations from the Zebrafish
Information Network (Zfin), IACUC protocols #AC18-011 and #AC21-009. Embryos
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were reared at 28.5°C in an enclosed incubation unit until treatment with exogenous
protein fragment.
Treatment of Embryos with exogenous ApoE1-151 fragments
Treatment of embryos began at 24 hpf during the 19-somite-prim-6 stage in
accordance with the Kimmel Staging Series (Kimmel et al., 1995). Zebrafish embryos
that were staged at the time of treatment to be above 24 hours (prim-5) or below 19 hpf
(20-somite stage) were excluded from experimentation. Incubation of embryos was
accomplished using a mixture of E3 media with various concentrations of nApoE41-151 or
nApoE31-151 protein fragments. Following staging assessments, embryos were allocated
to an incubation chamber in an even distribution depending on experiment. Embryos
were kept with a density of no more than 5 embryos in a minimum of 100 µL of E3
media + protein fragment per well for a 96 well plate. Control groups were raised in
identical conditions with the only difference being the absence of nApoE1-151 fragments
present in E3 media. Embryos were then placed in incubator for 24 hours of undisturbed
incubation at 28.5°C before being collected for experimentation.
Live Imaging (Light Microscope)
Live observations were recorded on an EVOS M5000 Light Microscope using
brightfield settings. Embryos were imaged at 4X for a general view of the embryo(s) and
10X or greater were used for tissue specific image acquisition. Mortality was assessed as
described below by comparing the number of nominal labels (1=Alive, 0= Dead/Nonviable) given to each group. A tally was taken via a contingency table in R to provide a
raw count for each individual treatment group. Normality and equal variance were tested
for prior to analysis. Each group count was then tested against each other via a Chi-
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square analysis and displayed via a mosaic display to indicate statistical significance by
shading and examination of the Pearson residual values.
Morphological Assessments
A set scale was generated across multiple standards resulting in a developmental
abnormality score (Figure 1). Embryos were scanned throughout the z-axis to identify
pigmentation, and gauge organogenesis at specific stages in coordination with the
Kimmel staging series. Results were then compared to untreated controls and the
comparable nApoE31-151 treatment groups.
Heart Rate Determination
Live imaging was also applied for mortality assessments of embryos in the
manner of identifying heartrate over the course of 10 second intervals. If no heart rate
was detected, stimulation of embryo through water movement was performed to verify
lack of response to stimuli. If no response to stimulation was found in combination with a
lack of heartbeat, subject was deemed non-viable. Heart rate was measured in a
continuous manner by beats per minute (bpm) as described above. Samples were
averaged by replicate to stabilize variation within groups. Five sets of heart rate
collection dates were tested through two-way ANOVA modelling with three treatment
groups (Control, nApoE31-151, and nApoE41-151) in R statistical software. ANOVA model
was assessed for assumptions after creation of model in R.
Results
Embryonic Survivability
Survivability of embryos beginning with fragment treatment at 24 hpf resulted in
a 90-100% reduction in viable embryos 48 hours after treatment began. nApoE41-151
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treated samples failed to recover after removal of treatment media. The survivability of
nApoE41-151 at a concentration of 25 μg/ml was reduced by 50% within 24 hours of
treatment, whereas nApoE41-151 at 50 μg/mL reduced survivability by 50% in under 12
hours. In contrast, similar concentrations of nApoE31-151 resulted in a smaller decline in
survivability (<15%).
Developmental Abnormalities
Developmental abnormalities produced higher scores within nApoE41-151 treated
samples compared with controls at the highest concentration level for 48 hpf (H(4)=-3.32,
p=0.0004).. nApoE31-151 also showed an increase in scores that appears treatment level
dependent (see Figure 3D) but lacked statistical significance from nApoE41-151 groups.
The highest treatment level for nApoE31-151 was significantly different from controls
(H(4)=-1.77, p=0.037). Features most commonly observed for nApoE41-151 groups were
lack/less pigmentation, lack of hindbrain folding at cerebellar primordium, lack of
detectable heartbeat/no response to stimulus, etc. Features most commonly observed in
nApoE31-151 treated samples were less pigmentation and deformed yolk sac. Each group
began to have a distinct appearance following treatment as shown in Figure 3A-C.
Heart Rate
Heart rate in the highest (50 μg/mL) nApoE41-151 treatment group decreased by
50% compared with controls and nApoE31-151 treated samples. The lowest nApoE31-151
treated samples were different from the highest treatment of nApoE41-151 but not from
controls.
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Conclusions
Assessing morphological changes following treatment with an amino-terminal
fragment of ApoE4 is a valuable application of in vivo research to understand the
biological context with which the molecular events. As shown in this chapter, treatment
with nApoE41-151 has concentration-dependent impact on decreasing survivability,
decreasing heart rate, as well as adversely affecting developmental embryogenesis.
Treatment with nApoE31-151 fragment in an identical fashion does not appear to hinder
development of embryos. Survivability curves indicate the effects from ApoE4 treatment
are long lasting and no recovery was observed in nApoE41-151 survivability rate from 4872 hpf after the treatment period had ended. Developmental abnormalities were observed
following treatment with nApoE41-151. Abnormalities frequently reported using welldefined criteria (see Figure 1) included: enlarged heart, enlarged pericardial cavity,
limited pigmentation, and limited hindbrain folding. Results indicate disruption to normal
development throughout the nervous and cardiovascular system following treatment with
nApoE41-151. Some of the effects that were noted in nApoE41-151 were also present in the
nApoE31-151 which were expected to behave more akin to the untreated control group;
this will be explored in the discussion chapter. However, the results for nApoE41-151
highlight an important role for the ApoE4 fragment in causing toxicity and support our
previous in vitro findings (Love et al., 2017; Pollock et al., 2020).

Table 2
Stages of Embryonic Development (Condensed from (Kimmel et al., 1995)). Stages of development were assessed
by evaluating the embryos in our projects in comparison to the scale provided below. Morphological features provided in the
table were then used to set a normal developmental timeline criteria for controls.

Tables
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Figures

Figure 1.
Project specific developmental abnormality scale.
Project scale was determined as a semi-qualitative measure for observing changes across
treatment groups. Scale was generated following observation of 30 embryos per treatment
group.
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Figure 2.

Survivability decreased in zebrafish embryos following exogenous
treatment with an amino-terminal fragment of nApoE41-151.
Embryos at 24hpf (prim-9 stage) were segregated into three groups: controls (untreated),
25 μg/mL or 50 μg/mL nApoE31-151, and 25 μg/mL or 50 μg/mL nApoE41-151. Embryos
that lacked a heartbeat for 10 seconds were stimulated to induce movement. If no
movement or heartbeat was detected, embryos were considered to be non-viable. Data
represent 3 independent trials, n=5 fish/treatment.
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A sublethal concentration of nApoE41-151 leads to morphological
abnormalities in zebrafish embryos at the hatching phase.
Representative light phase contrast microscopic images following live imaging of
embryos at 48hpf following a 24-hour period with respective treatments (Control, 25
µg/mL of nApoE31-151, or 25 µg/mL of nApoE41-151. A: Arrows point to consistent
morphological changes as compared to untreated controls that are healthy and
categorized as having a developmental abnormality score of <1.0) (Panel A). The blue
arrows designate pigmentation changes; orange arrows designate cerebellar primordium
junction differences in the hindbrain. B: Exogenous treatment with nApoE31-151 impacted
pigmentation pattern in otherwise healthy embryos. Embryos in this category were most
likely to receive a score of <1. C: 24-hour incubation of a sublethal concentration of
nApoE41-151 resulted in developmental abnormality scores >3. Embryos in this category
were typically observed to be delayed in development with limited hindbrain folding
(orange arrow), limited or lacking pigmentation (blue arrow), as well as enlargement of
the cardiac cavity (red arrow). D. Quantitative developmental abnormality scores for each
treatment group following treatment of embryos for 24 hours with respective E3 (orange
bar), E4 (gray bar) at 25µg/mL and E3 (gray bar), E4 (yellow bar) at 50 µg/mL.
nApoE41-151 25ug/mL was significantly different from controls (H(4)=-2.43, p=0.0074).
nApoE41-151 50μg/mL was significantly different from controls (H(4)=-3.32, p=0.0004).
nApoE31-151 was different from controls (H(4)=-1.77, p=0.037) All other comparisons
were not significant. Errors bars represent ±S.E.M., Control(n=5), E325 and E350(n=2),
E425 and E450 (n=4). *p<0.05, **p<0.01, ***p<0.001 E. Heart rate data obtained from
live microscope analyses in 25μg/mL and 50 μg/mL treatment groups nApoE31-151 and
nApoE41-151 compared to non-treated controls. nApoE41-151 25ug/mL was significantly
different from controls (H(4)=1.77, p=0.038). nApoE41-151 50μg/mL was significantly
different from nApoE31-151 25μg/mL (H(4)=1.94, p=0.026) and controls (H(4)=2.665,
p=0.0039). Errors bars represent ±S.E.M., Control(n=5), E325 and E350(n=2), E425 and
E450 (n=4). All other comparisons were insignificant. *p<0.05, **p<0.01, ***p<0.001
Figure 3.
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CHAPTER THREE: MOLECULAR EFFECTS
In the present chapter, the effects of nApoE41-151 were examined from a molecular
context. The proposed experiments provide proof of concept for the in vitro research
performed previously by our lab with the nApoE1-151 fragments and BV2 microglial cells.
In this chapter, a lactate dehydrogenase (LDH) assay was undertaken using zebrafish
homogenates to assess cytotoxicity. The LDH assay reports levels of cytotoxicity by
quantifying the release of LDH through a chain reaction that precipitates a color change
proportional the amount of LDH that is in the medium (Scientific). This assay typically
works with specificity since LDH is a cytosolic enzyme found within cells. When a cell
incurs damage to the plasma membrane, this allows for the cytosolic enzyme to enter the
prepared media (Lungu-Mitea et al., 2021). Our study adjusted the use guidelines
proposed in (Diamantino et al., 2001; Maharajan et al., 2018) to raise the number of 48
hpf embryos to 15 per sample group. Identification of a known apoptotic marker,
activated, cleaved caspase-3 (17 kDa and19 kDa), was also employed to assess the
activation of apoptotic pathways as a mechanism of cell death (Lossi et al., 2018).
Previous studies performed in our lab were restricted by utilizing transformed,
BV2 microglial cell lines (Love et al., 2017). By using a single cell type, the research
lacks information on whether nApoE41-151 interacts with neurons and more specifically
could also traffic to the nucleus similar to the results from BV2 microglial cells.
Trafficking to the nucleus is a vital step in understanding whether the actions of
nApoE41-151 are direct through a role as a transcription factor or through an indirect
mechanism. The extension of our previous work into a complex tissue environment fills a
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gap in the knowledge of how nApoE41-151 might interact with various cell types including
neurons. Immunohistochemical methods such as immunofluorescence were applied to
look examine cellular localization of ApoE fragments compared to untreated controls. To
accomplish this goal, the ApoE fragments were synthesized with 6X-His-tag which
allows for the identification of the fragments in culture or tissue experiments through the
application of an anti-6X His-tag antibody. To identify neuronal cells, a NeuN antibody
was applied to zebrafish sections. The NeuN reacts to rbfox3, a neuron specific nuclear
protein. Additionally, utilizing an organismal system with orthologues similar to those
expressed in AD (MAPT; mapta and maptb) allowed the opportunity to screen for ADlike tau pathology using triple label confocal microscopy. Immunostaining was
performed on fixed zebrafish tissue sections utilizing PHF-1, a marker for
hyperphosphorylated Tau at S396/404. My working hypothesis for this the first half of
this chapter is that we will detect increased cytotoxic biomarkers in nApoE41-151 over
control and nApoE31-151 treatment groups. For the second half of the chapter, we predict
that nApoE41-151 will be detected within neuronal nuclei and develop potential tau
pathology compared to control or nApoE31-151 treated groups.
Materials and Methods
Zebrafish Homogenate Preparation and Cytotoxic Assays
Samples for analysis in Pierce Lactate Dehydrogenase (LDH) and western blot
were generated by homogenizing 15 embryos per treatment over ice in 0.1 M Tris-HCL,
pH,7.2. Homogenized samples were then centrifuged at 3000 x g for 5 minutes at 4℃.
The supernatant was then collected for use in LDH and western blot analysis. LDH
measurements and western blot analyses were conducted as previously described utilizing
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whole embryo homogenates (Love et al., 2017). Briefly, to determine the involvement of
caspase-3, we utilized the cleaved caspase-3 (1:1,000) antibody from Cell Signaling
Technology, which detects both the 17 and 19 kDa active domains of caspase-3. To
ensure equal protein loading among various samples, embryo homogenates were assayed
(BCA) for protein content. In addition, transferred SDS-PAGE gels were stained with
Coomassie blue to ensure equal protein loading.
Immunohistochemistry
For all immunohistochemical procedures in this study, a standard protocol was
followed for tissue preparation, and preparation of the slides. At the conclusion of
treatment experiments, embryos were sacrificed prior to manual removal of chorion.
Following de-chorionation, embryos were fixed in 4% paraformaldehyde (PFA)/PBS
overnight at 4°C and prepared for 5 µm paraffin-embedded sectioning using a Leica
RM2235 Microtome at 4 °C. After slide preparation. Paraffin-embedded sections were
used for staining following rehydration and a series of washes in phosphate-buffered
saline with 0.05% Tween 20 (PBT). Blocking of sections for non-specific staining was
accomplished using a standard incubation buffer consisting of 1% Normal Goat Serum,
2% Bovine Serum Albumin in PBT for 2 hours at room temperature (RT). Primary
antibodies, detailed in Table 3, were incubated with slides for 18-24 hours at 4°C.
Sections were then washed in triplicate for 5 minutes with PBT. Slides were then
incubated in the appropriate secondary antibody for 1 hour at RT. Following the final
wash, DAPI (nuclear stain) -infused soft mount was placed on slides and allowed to set
before coverslip addition. Sections were assessed for preliminary staining with EVOS
M5000 light cubes at lowest intensity settings. Sections were then kept in the dark at 4°C
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until used for confocal imaging. Confocal assessment of the localization of nApoE41-151
in neuronal cell populations was as previously described. All images and z-stacks
generated were obtained using Zeiss Microscope, LSM 510 Meta confocal imaging
system (Carl Zeiss, Oberkochen, Germany) and processed using Zen blue edition (Carl
Zeiss, Göttingen, Germany).
Results
Toxicity
Using methods detailed in chapter one, 48hpf nApoE41-151 treated samples
contained more than expected non-viable embryos classified by our standards of lacking
a heartbeat and being unresponsive to stimulation (p=1.17x 10-13) (Figure 4A).
Pierce Lactate Dehydrogenase Assay
Treatment of zebrafish embryos with exogenous nApoE41-151 led to an increase in
the release of LDH, however, no significance was determined (Figure 4B). LDH release
is a down-stream indicator of cell death or damage to the plasma membrane. Control
groups represent the baseline expectation for comparison.
Caspase-3 Western Blot
Activated caspase-3 was identified in nApoE41-151 treated samples using an
antibody that recognizes cleaved caspase-3 peptides (17 and 19 kDa), but not in untreated
controls. Coomassie blue staining of transferred gel slabs indicated an equal protein
loading in both untreated controls and nApoE41-151 treated sample groups (see Figure
4C). Equal protein loading with detection of cleaved caspase-3 indicates activation
apoptotic pathways following treatment of zebrafish embryos with 50 μg/mL nApoE41151.
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Immunohistochemistry
Triple label confocal microscopy confirmed nuclear staining in nApoE41-151
treated samples, where peri-nuclear staining was observed in nApoE31-151 in NeuN
labeled neurons (see Figure 5). In parallel experiments, we examined whether we could
detect tau pathology using the PHF-1 antibody. As depicted in Figure 7, labeling of PHF1 in nApoE41-151 treated samples was present and more distinguishable than in controls or
nApoE31-151 treated samples for 48 hpf (see Figure 6) and more distinguishable than
controls at 72 hpf (see Figure 7).
Conclusions
LDH results demonstrated that following exogenous treatment with nApoE41-151
increased cytotoxicity in a concentration-dependent manner. Activated caspase-3
detection supports a role for the activation of apoptotic pathways as a mechanism of cell
death. Results from confocal experiments supports the hypothesis that nApoE41-151
traffics to neuronal cell nuclei. Finally, results from triple-label confocal microscopy
support the presence of tau pathology in nApoE41-151 treated samples as compared to the
controls or the nApoE31-151 group in 48 hpf samples. Data looking at 72 hpf was more
compelling, identifying that at 24 hpf post treatment, tangle pathology is present and not
observed in non-treated controls.

Antibodies used in Immunohistochemistry Experiments.

PHF-1 (1:250, Mouse polyclonal)

NeuN (1:50, Mouse polyclonal)

nApoE31-151

Anti-6x His Tag (1:500, Rabbit
polyclonal)

Tau phosphorylated
396 and 404

rbfox3a,
Neuronal nuclei

and nApoE41-151

Reactivity

Primary Antibodies

AF 555 1:200, Donkey, Anti-Mouse)

AF 555 (1:200, Donkey, Anti-Mouse)

AF 488 (1:500, Goat, Anti-Rabbit)

Secondary Antibodies

recombinant ApoE fragments in conjunction with either NeuN or PHF-1 for experiments.

Dr. Pete Davies (Albert
Einstein College of Medicine,
Bronx, NY), ThermoFisher

Abcam Inc, ThermoFisher

Abcam, Inc, ThermoFisher

Source

Antibodies were used in immunohistochemistry experiments detailed above. Ant-6x His Tag antibodies were used to identify

Table 3.

Tables
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Figures

Figure 4.

Measurements of LDH and apoptosis indicate a cytotoxic role for
nApoE41-151 (A-C).
(A)The Mosaic Plot depicts mortality based on a lack of heartbeat and response to
physical stimuli following exogenous treatment of 48hpf zebrafish embryos with either
25 µg/mL nApoE31-151 or nApoE41-151 for 24 hours. The blue filled region of the bar
graph designates 25 µg/mL treatment of nApoE41-151 which led to a significant portion of
the embryos being designated as dead. The red dotted portion of the bar graphs indicates
less than expected were alive (p=1.17e-13). All blank cells indicate the sample group
followed the estimated trend. Data indicated significant morality for only the nApoE41-151
group. N=3 independent experiments, 15 embryos/treatment. (B) Represents the results
of LDH analysis utilizing 50 µg/ml concentrations for both E3 and E4 fragments. Data
established trend but not significance (p>0.05). Error bars show +/-SEM. (C) Results
from western blot with an activated caspase-3 antibody. The presence of the two small
domains of caspase-3 indicates activation of apoptotic pathways within nApoE41-151
treated samples. Coomassie blue stained transfer gel shown below to verify protein
loading.
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Figure 5.
Exogenous treatment of zebrafish embryos with amino-terminal
fragments of nApoE41-151 leads to nuclear localization. (A-D).
Representative images from confocal immunofluorescence in 5mm paraffin embedded
sections of non-treated control 48hpf zebrafish embryos that were stained with DAPI (A),
NeuN (1:50). (B), anti-His antibody (1:500) (C), and the merged image in Panel (D).
There was no detection of any nApoE1-151 fragments in untreated control neuronal cells as
indicated by the lack of labeling in Panel C. (E-H) Identical to Panels A-D with the
exception that embryos were exogenously treated for 24 hours with 25 µg/ml of
nApoE31-151. Perinuclear localization of nApoE31-151 was evident (Panel G and H,
arrows) under these conditions. (I-L) Parallel experiments as in Panels E-H with the
exception that zebrafish embryos were treated exogenously for 24 hours with 25 µg/mL
of nApoE41-151. In this case, strong nuclear localization of nApoE41-151 was evident
within neuronal cells (Panels K and L, arrows). For both fragments, staining appears
punctate and co-localized with NeuN and DAPI. All images were captured within the
area of the cerebellum and fourth ventricle. Data are representative of three independent
experiments. All scale bars represent 10 µm.
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Figure 6.

Tau Pathology present after treatment with exogenous nApoE41-151
Fragment in 48hpf zebrafish brain. (A-D).
Representative 40x images from confocal immunofluorescence in 5μm paraffin
embedded sections of non-treated control 48hpf zebrafish embryos that were stained with
DAPI, PHF-1 (1:250), and Anti-6x His Tag antibody to detect nApoE41-151 (1:500). (EH): Parallel experiments as in Panels A-C with the exception that zebrafish embryos
were treated exogenously for 24 hours with 25 µg/mL of nApoE41-151. Little to no PHF-1
dectected at 48hpf in nApoE31-151. (I-L): Parallel experiments as in Panels A-C with the
exception that zebrafish embryos were treated exogenously for 24 hours with 25 µg/mL
of nApoE41-151. Light detection of PHF-1 compared to control and nApoE31-151 sections.
All scale bars represent 10 µm.
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Figure 7.

Tau Pathology present after treatment with exogenous nApoE41-151
Fragment in 72hpf zebrafish brain. (A-D).
Representative 40x zoomed images from confocal immunofluorescence in 5μm paraffin
embedded sections of non-treated control 72hpf zebrafish embryos that were stained with
DAPI, PHF-1 (1:250), and Anti-6x-His- Tag antibody to detect nApoE41-151 (1:500). (EH): Parallel experiments as in Panels A-C with the exception that zebrafish embryos
were treated exogenously for 24 hours with 25 µg/mL of nApoE31-151 then given 24 hours
in clean media before using for experiment at 72hpf. Presence of PHF-1 staining overlap
with nApoE31-151 noted with red arrow, PHF-1 staining does not appear to change
structure of protrusions from nuclei (E-H). (I-L): Parallel experiments as in Panels A-C
with the exception that zebrafish embryos were treated exogenously for 24 hours with
25µg/mL of nApoE41-151 then given 24 hours in clean media before using for experiment
at 72hpf. Presence of AD-like tau pathology noted with red arrows; PHF-1 labeling that
overlaps with nApoE41-151 appears aggregated compared to staining in nApoE31-151 (I-L).
All scale bars represent 10 µm.
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CHAPTER FOUR: BEHAVIORAL EFFECTS
Overview
In the fourth chapter of this thesis, the focus is centered on the potential
behavioral deficits following treatment of zebrafish with nApoE41-151. Behavioral effects
in this thesis provides relevant context to the molecular and morphological data provided
in previous chapters. Embryonic motor behavior begins around 24-27 hours postfertilization with spontaneous tail twitching with response to stimuli beginning shortly
after (Saint-Amant & Drapeau, 2000). Initial twitches and response to stimuli prior to the
hatching period (<48hpf) have been shown to exist within a rostral spinal cord loop
(Pietri et al., 2009; Saint-Amant & Drapeau, 2000). The development of a hindbrain
integrated circuit controlling spontaneous tail movement and the ability to respond
rapidly to touch stimulus occurs after Mauthner cell maturity around the time of hatching
(Eaton et al., 1977). Assessing the behavior of zebrafish in larvae (post-hatching) is
therefore more aligned with mature motor circuitry in zebrafish.
My thesis employed modifications of previously reported methods in order to
assess whether nApoE41-151 treatment impacts the presence of either the spontaneous tail
flick behavior referred to herein as the tail flick test (TFT) or touch-response test referred
to herein as the touch-evoked movement response (TEMR). The TFT experimental
design utilized in the present study is a modification on one employed by Roberts et al.
(Roberts et al., 2020). The TEMR design was based on the described behavior in (Kalueff
et al., 2013). TFT and TEMR tests utilized larvae approximately at 72 hpf +/-2 hours to
align data with the hindbrain associated circuit. Both tests are valuable in determining
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proper development of motor behaviors. Our design would be aligned with a predicted
hypoactive response, meaning we hypothesize that nApoE41-151 treated samples will be
the lowest performing group in both assays.
Materials and Methods
Tail Flick Behavioral Test
Larvae were acclimated to the testing area for 2 minutes prior to experimentation.
Five-minute videos were taken of each larvae using a Motic MGT 101 Moticam
recording device with an LED-60T-B light ring. Videos were recorded down each
treatment group column, then across well rows in a 96-well petri dish. Immediately
following testing, the samples were euthanized using IACUC and University Guidelines,
preserved in 4% PFA/PBT, then stored in 100% ethanol at -20℃. During each recording
individual larva were documented using a numerical code to designate treatment groups
for a single-blind procedure, in which one researcher recorded and encoded video names
for treatment and a second researcher analyzed coded videos. Scoring was completed by
examining videos while documenting the number of tail flicks in total for each larva over
a 5-minute span, then dividing the total by 5 (Tail Flicks per Minute). A single tail flick
was determined by counting the number of times each larva bent their tail away from
center and returned to the center axis. Samples were prepared by averaging 5 tail flicks
per replicate over the course of 5 replicates for trial one using nApoE31-151 10 μg/mL
(final concentration) and nApoE41-151 at a final concentration of 10 μg/mL. Ten
micrograms per milliliter was the initial concentration we chose to identify whether a
reduced treatment level (<50% of a sublethal concentration) would evoke behavioral
responses prior without a decrease in survivability; 10 replicates for trial two using
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nApoE31-151 25 μg/mL and nApoE41-151 25 μg/mL (final concentrations). Concentrations
were raised in trial 2 to align data with other experimental outcomes as opposed to
visualizing a minimum treatment effect. Data analyzed for each trial represent the
averaged results for each collection date. Data was analyzed through two-way ANOVA
modeling with three treatment groups (Control, nApoE31-151, and nApoE41-151) in R
statistical software. The ANOVA model was assessed for assumptions after creation of
model in R.
Touch Evoked Movement Response Assay
Individual larvae at 72hpf were moved to a 14x14 mm round glass bottom petri
dish filled with E3 Media 2 minutes prior to testing for acclimation under light conditions
for testing. Two-minute videos were recorded on Motic MGT 101 Moticam recording
device with an LED-60T-B light ring. After the start of the recording at time (T=0),
embryos were tapped lightly with a blunt probe every 15 seconds to allow the media to
settle and original movement to terminate. Directly following testing, larvae were
euthanized using IACUC and University Guidelines, preserved in 4% PFA/PBT, then
stored in 100% ethanol at -20℃. Videos were analyzed in Noldus Behavioral Software
version 15.0. Criteria for scoring was based on the number of responses following the
evoked stimulus. Data was grouped by treatment and analyzed in R statistical software.
Data was assessed for normality and variance. The number of responses to the evoked
stimulus was analyzed using One-Way ANOVA.
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Results
Tail Flick Test Assay
In trial 1 of TFT (Figure 8A), nApoE41-151 performed the least number of tail
flicks per group with >50% reduction from untreated controls. Treatment of zebrafish
larvae with nApoE31-151 performed similarly to controls. No difference was significant
across any group (F (2,12) = 2.49, p=0.125). Trial 1 was repeated due to numerous
confounding variables explained in the conclusion section.
Trial 2 of TFT (Figure 8B) spontaneous tail flicks were <1 per minute for all
treatment groups. nApoE31-151 outperformed tail flick median of all other groups, with the
nApoE41-151 treated cohorts were again at the lowest performing group. No significance
was detected between any groups compared (F(2,27)=1.24, p=0.305).
Touch-Evoked Movement Response Assay
For the TEMR, control groups and nApoE31-151 treated groups responded to 90%
of the stimulations applied. nApoE41-151 treated samples responded to fewer than 50% of
stimulations. Significance was not achieved groups (F(12)=1.482, p=0.266). Results are
shown in Figure 9.
Conclusions
The first TFT assay appeared initially to indicate strong spontaneous tail flick
activity in controls and nApoE31-151 treated samples whereas a reduced response was
found in nApoE41-151 treated samples (Figure 8A). The data from this trial, however, had
large variation within groups. Some of the pitfalls of this first TFT trial were the
recording area for this study. The area itself was a shared research space that did not have
enclosed spaces to perform sensitive experiments. As such, there were external
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disturbances throughout the area during recordings which potentially influenced the
results by adding unintentional stimulation to the testing zebrafish. The TFT assay was
repeated due to several those confounding variables (Figure 8A). TFT trial 2 (Figure 8B)
cohorts demonstrated minimal spontaneous tail flick behavior in a controlled
environment. The lack of response in the trial, while counterintuitive to our original
hypothesis, indicates there is limited motor initiation in our 72hpf larvae in an
unstimulated environment.
Despite the lack of statistical significance in the data for the TEMR, the presence
of a consistent trend remains with untreated controls responding to over 90% of the
stimuli on average while nApoE31-151 treated larvae responded to >80%, and nApoE41-151
responded to fewer than 50% of the stimulations. The nApoE41-151 -treated cohorts
remained the lowest scoring treatment category for TEMR. There was a 50% reduction in
response rate from nApoE41-151 from the control group. Data while following a trend for
motor impairment following treatment with nApoE41-151 was not statistically significant
from untreated controls (F(2,12)=1.482, p=0.266). This experiment had its own pitfalls
such as the lack of using a structured testing to test if any difference could be observed
from response to either a left- or right-side tail stimulus. Additionally, the testing
14x14mm petri dish had moved in several videos during testing which required a prompt
reset of the dish back into focus. The latter of the two was better controlled for in video
analyses as the reviewer could exclude responses that happened during the resetting
process. Lastly, there was no random sampling applied to the testing method, controls
were analyzed first, then nApoE31-151, followed by nApoE41-151 for every trial. These
factors likely contributed to variation for this test.
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Figures

Figure 8.

TFT trials finds no difference in unstimulated muscle twitches
between treatment groups (A-C).
(A) TFT trial 1 results were inconclusive with no difference detectable among any groups
tested despite a declining trend in data (F (2,12) = 2.49, p=0.125). Groups for Control,
ApoE31-151 10μg/ml (E310), and ApoE41-151 10μg/ml (E410) were assessed via video
monitoring to determine number of tail flicks per minute that were then averaged per
group for each trial. Data are representative of N=5 trials, for a total of 25 embryos per
group. The median is depicted in boxplot with quantiles. Potential outliers are shown as
dots (B) Trial 2 reported limited spontaneous tail flick activation from every group with
no difference detectable between groups (F(2,27)=1.24, p=0.305). (C) Diagram
visualizing the test, figure in center is larva in well plate from the perspective of the
recording microscope. Red dotted line is the inferred midline of the larva from the
sagittal plane. The solid lines were used as a reference for video scorers to grade response
as a tail flick. Tail flicks were expected to fall between 45°.
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Figure 9.

Touch-Evoked Movement Response outcomes lack significance but
identify a clear decreasing trend through treatment groups.
ApoE4 treatment groups on average responded 50% less than Controls (F(12)=1.482,
p=0.266). Controls had a 90% response rate to the stimulus, whereas nApoE41-151
responded to fewer than 50% of invoked stimulus.
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CHAPTER FIVE: DISCUSSION
Mechanistic research into the pathophysiological relationship between harboring
the APOE4 allele and the development of late-onset AD have been on-going for decades.
Prior research from our lab supports the hypothesis that ApoE4 fragmentation via MMP9 may contribute to AD pathology and inflammation (Love et al., 2017). Other studies
have also shown neurotoxic and pro-inflammatory responses to the fragmentation of
ApoE4 (Dafnis et al., 2012; Tolar et al., 1997; Zhou et al., 2006). The research provided
in this thesis brings in vivo relevance and expands on our previous studies utilizing
transformed BV2 microglial cells to understand nApoE41-151 in an organismal context.
Using exogenously applied nApoE41-151 to assess morphological effects in
zebrafish, our results indicate a potential interaction between nApoE41-151 with nervous
system, cardiovascular, and pigmentation development. The nervous system was visibly
impacted by the lack of hindbrain folding that is typical in 48hpf zebrafish along the
cerebellar primordium Figure 3C. Additionally, exogenous nApoE41-151 treatments at
both a low (25μg/mL) and high (50μg/mL) concentrations produced significant
differences from controls in terms of developmental abnormalities and reduced heart
rates. The morphological results of enlargement of hearts following nApoE41-151
treatment supports the link between inheritance of APOE4 and an increased risk of
cardiovascular disease (Carlos Lahoz, 2001). Our immunohistochemical results may shed
light on our heart rate effects in nApoE41-151. Nuclear staining in neurons labeled with
NeuN have been observed in the hindbrain region around the medulla oblongata (MO)
which regulates heart rate. Our research supports the likelihood that nApoE41-151
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contributes to a cytotoxic environment through upregulation of key apoptotic regulators
such as caspase-3. These data support the hypothesis that nApoE41-151 may destabilize the
hindbrain networks during the incubation period. These results open an avenue for further
research into whether nApoE41-151 directly impacts cardiovascular tissue or whether there
is a downstream effect from the presence of nApoE41-151 in the hindbrain.
Additionally, increased detection of nApoE41-151 compared to controls within the
hindbrain region could be an avenue for the effects observed in the TEMR assay. The
touch escape response and spontaneous tail flicks are both proposed to be regulated by
the Mauthner cells located in the zebrafish hindbrain (Eaton et al., 1977; Liu & Fetcho,
1999). Treatment of zebrafish larvae with nApoE41-151 led to less than half of the
stimulation attempts whereas control responded to over 90% and nApoE31-151 responded
to over 80%. Future experiments for this study would be to evaluate at what stage in this
behavior does nApoE41-151 interfere: initiation or execution of the behavioral response.
Initiation of the response would imply the sensation of the stimulus was never received
through the rohon-beard cells or the dorsal root ganglia which have been shown to share
the responsibility of tactile sensation during the 72hpf period (Pietri et al., 2009; SaintAmant & Drapeau, 2000).
Another important result from these studies was the increased presence of PHF-1
labeling in nApoE41-151 treated samples that resembles AD-like tau pathology beginning
at 48hpf and increasing at 72hpf (as seen in Figures 6 and 7). These findings support that
nApoE41-151 may promote tau pathology, a hallmark feature seen in human AD pathology
(Lin et al., 2018). The observed tau pathology can lead to disruptions in axonal health
which in turn, can have deleterious effects on neuronal signaling and axonal transport
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(Forner et al., 2017; Kowall & Kosik, 1987). These results help to clarify that treatment
with nApoE41-151 leads to a dysfunctional, disease state. Future steps for this aspect of my
thesis include pursuing a transgenic model that carries an inserted nApoE41-151 insertion
to allow continuous expression of the protein fragment. A transgenic model will help to
provide a more consistent model for nApoE41-151 effects that are expressed consistently
throughout embryogenesis and into adulthood as opposed to our 24-hour incubation
period. We expect to pursue more behavioral testing in the future for locomotion and
memory for mutant nApoE41-151 compared to wild-type controls.
Taken together, the results of my thesis stand as a proof-of-concept that extends
the results of the prior in vitro experiments from our lab to an in vivo vertebrate model
system. This thesis also fills gaps within the scientific literature as to how an aminoterminal ApoE4 fragment can influence the progression of embryogenesis, and that
ApoE4 can influence the development of the cardiovascular system.
In conclusion, this work supports the hypothesis that the presence of aminoterminal ApoE4 fragments can negatively impact developmental outcomes, promote
cytotoxicity, and stimulate a toxic gain-of-function resulting in an AD-like tau pathology.
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